"Parkinson Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Descriptor ID |
D010300
|
| MeSH Number(s) |
C10.228.140.079.862.500 C10.228.662.600.400 C10.574.812
|
| Concept/Terms |
Parkinson Disease- Parkinson Disease
- Idiopathic Parkinson's Disease
- Lewy Body Parkinson Disease
- Lewy Body Parkinson's Disease
- Primary Parkinsonism
- Parkinsonism, Primary
- Parkinson Disease, Idiopathic
- Parkinson's Disease
- Parkinson's Disease, Idiopathic
- Parkinson's Disease, Lewy Body
- Idiopathic Parkinson Disease
- Paralysis Agitans
|
Below are MeSH descriptors whose meaning is more general than "Parkinson Disease".
Below are MeSH descriptors whose meaning is more specific than "Parkinson Disease".
This graph shows the total number of publications written about "Parkinson Disease" by people in this website by year, and whether "Parkinson Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 1997 | 6 | 2 | 8 |
| 1998 | 6 | 1 | 7 |
| 1999 | 14 | 1 | 15 |
| 2000 | 10 | 2 | 12 |
| 2001 | 16 | 0 | 16 |
| 2002 | 13 | 1 | 14 |
| 2003 | 12 | 2 | 14 |
| 2004 | 11 | 3 | 14 |
| 2005 | 18 | 5 | 23 |
| 2006 | 17 | 2 | 19 |
| 2007 | 21 | 1 | 22 |
| 2008 | 18 | 4 | 22 |
| 2009 | 21 | 4 | 25 |
| 2010 | 23 | 1 | 24 |
| 2011 | 21 | 2 | 23 |
| 2012 | 17 | 1 | 18 |
| 2013 | 14 | 1 | 15 |
| 2014 | 24 | 1 | 25 |
| 2015 | 15 | 4 | 19 |
| 2016 | 11 | 4 | 15 |
| 2017 | 19 | 2 | 21 |
| 2018 | 19 | 2 | 21 |
| 2019 | 18 | 1 | 19 |
| 2020 | 14 | 0 | 14 |
| 2021 | 27 | 2 | 29 |
| 2022 | 21 | 0 | 21 |
| 2023 | 27 | 0 | 27 |
| 2024 | 23 | 3 | 26 |
| 2025 | 24 | 4 | 28 |
| 2026 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Parkinson Disease" by people in Profiles.
-
Apathy, effort-based decisions and brain integrity in Alzheimer's and Parkinson's diseases. Brain. 2026 May 05; 149(5):1635-1649.
-
Integration of cross-species multi-omics with in vivo experimental validation identifies Parkinson's disease therapeutic targets and novel risk factors within endolysosomal pathway subnetworks. Neurobiol Dis. 2026 05; 222:107364.
-
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease. Nat Aging. 2026 Mar; 6(3):626-635.
-
Assessment of Angiopep-2 targeting intracerebral a-synuclein aggregates in a PFF-induced rat model of Parkinson's disease based on 7T CEST-MRI. Brain Res Bull. 2026 Apr; 237:111783.
-
Neuroimaging correlates of cognitive stages in Parkinson's disease: A multimodal MRI study. Clin Neurol Neurosurg. 2026 05; 264:109343.
-
Faecal microbiota transplant for Parkinson's disease: promises and future directions. Brain. 2026 Jan 08; 149(1):59-70.
-
An algorithmic procedure for measuring deep brain stimulation-induced capsular activation using motor evoked potentials. J Neural Eng. 2025 Dec 30; 22(6).
-
Motor evoked potentials as a side effect biomarker for deep brain stimulation. Clin Neurophysiol. 2026 Mar; 183:2111499.
-
Yawning-related tremor in patients with Parkinson's disease. Parkinsonism Relat Disord. 2026 Feb; 143:108162.
-
GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions. Front Endocrinol (Lausanne). 2025; 16:1708565.